Page last updated: 2024-08-25

9-aminocamptothecin and Neoplasms

9-aminocamptothecin has been researched along with Neoplasms in 31 studies

Research

Studies (31)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	17 (54.84)	18.2507
2000's	13 (41.94)	29.6817
2010's	1 (3.23)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, P; Huang, C; Li, K; Liu, M; Wang, L; Xue, J; Yan, Z; Zhu, Z	1
Chiang, C; Hamilton, A; Hazarika, M; Hochster, H; Hornreich, G; Liebes, L; Muggia, FM; Newman, E; Potmesil, M; Sorich, J; Wadler, S	1
Abbruzzese, JL; Madden, TL; Newman, RA; Tran, HT; Xiong, HQ	1
Dahut, W; Grem, JL; Ismail, AS; Leguizamo, J; Liang, MD; Pang, J; Quinn, M; Takimoto, CH	1
Belani, CP; Egorin, MJ; Fakih, M; Jin, R; Jung, LL; Potter, DM; Ramanathan, RK; Strychor, S; Trump, DL; Walko, C; Zamboni, WC	1
Egorin, MJ; Goel, S; Iqbal, T; Mani, S; Parise, RA; Repinski, TV; Strychor, S; Zamboni, WC	1
Davis, TA; Egorin, MJ; Jung, LL; King, CR; Mani, S; Marsh, S; Maruca, LJ; McLeod, HL; Parise, RA; Potter, DM; Ramanathan, RK; Strychor, S; Zamboni, WC	1
Barrows, LR; Marshall, KM; Pond, CD	1
O'Leary, J; Sewak, S; Sorich, J	1
Sinha, BK	1
Allegra, C; Arbuck, S; Chen, A; Corse, W; Dahut, W; Grem, J; Grollman, F; Hamilton, JM; Harold, N; Liang, M; Lieberman, R; Nakashima, H; Sorensen, M; Takimoto, C	1
Dancey, J; Eisenhauer, EA	1
Bryant, M; Eder, JP; Grossbard, M; Huberman, M; Hurwitz, S; Kinchla, N; Kufe, DW; Lynch, T; Rodriguez, D; Rubin, E; Schnipper, L; Shapiro, C; Shulman, L; Stone, R; Supko, J; Toppmeyer, D; Vosburg, E; Xu, G	1
Allegra, CJ; Arbuck, SG; Cantilena, LR; Chen, AP; Dahut, W; Grem, JL; Hamilton, JM; Harold, N; Liang, MD; Lieberman, R; Nakashima, H; Takimoto, CH	1
Allegra, CJ; Arbuck, SG; Band, RA; Cantilena, LR; Chen, AP; Dahut, W; Grem, JL; Hamilton, JM; Harold, N; Liang, MD; Lieberman, R; Marino, MT; Nakashima, H; Takimoto, CH	1
Loos, WJ; Nooter, K; Schellens, JH; Sparreboom, A; Stoter, G; Verweij, J	1
Eisenhauer, EA; Feld, R; Firby, PS; Goldberg, RA; Manzo, J; Michael, M; Moore, MJ; Oza, AM; Siu, LL; Thiessen, JJ; Wainman, N	1
Bryant, M; Eder, JP; Kufe, DW; Lynch, T; Shulman, LN; Supko, JG; Vosburgh, E; Xu, G	1
Arbuck, SG; Kieffer, LV; Takimoto, CH	1
Fleming, GF; Iyer, L; Janisch, L; Mani, S; Ratain, MJ; Schilsky, RL; Wang, X	1
Bernstein, M; Blaney, S; Casto, DT; Dubowy, R; Grier, H; Kretschmar, C; Langevin, AM; Pratt, C; Thomas, PJ; Vietti, T; Weitman, SD	1
de Jonge, MJ; Loos, WJ; Nooter, K; Porro, MG; Punt, CJ; Sparreboom, A; Verweij, J	1
Bartel, S; Bharti, A; Hurwitz, S; Levy, S; Lynch, C; Rosowsky, A; Rubin, E; Toppmeyer, D; Trites, D; Wood, V	1
Dallaire, BK; de Jonge, MJ; Loos, WJ; Sparreboom, A; Verweij, J	1
Beijnen, JH; Herben, VM; Hillebrand, MJ; Lieverst, J; Porro, MG; Schellens, JH; Schoemaker, NE; Schot, M; ten Bokkel Huinink, WW; van Gijn, R	1
Dallaire, BK; de Jonge, MJ; Gelderblom, AH; Loos, WJ; Planting, AS; Punt, CJ; Sparreboom, A; van Beurden, V; van der Burg, ME; van Maanen, LW; Verweij, J; Wagener, DJ	1
Downey, A; Hamilton, A; Hochster, H; Hornreich, G; Liebes, L; Muggia, F; Potmesil, M; Sorich, J; Wasserstrom, H	1
Takimoto, CH; Thomas, R	1
Takimoto, CH	1
Allegra, CJ; Arbuck, SG; Band, RA; Chen, AP; Corse, W; Cottrell, J; Dahut, W; Grem, JL; Hamilton, JM; Harold, N; Liang, M; Llorens, V; Monahan, BP; Shapiro, JD; Smith, JA; Takimoto, CH; Thomas, RR; Wright, J	1
Berg, SL; Blaney, SM; Bomgaars, L	1

Reviews

6 review(s) available for 9-aminocamptothecin and Neoplasms

Article	Year
Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs, 1995, Volume: 49, Issue:1 Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Humans; Irinotecan; Neoplasms; Podophyllotoxin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan	1995
Current perspectives on camptothecins in cancer treatment. British journal of cancer, 1996, Volume: 74, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan	1996
DNA topoisomerase I inhibitors. Cancer chemotherapy and biological response modifiers, 1997, Volume: 17 Topics: Animals; Antineoplastic Agents; Antiviral Agents; Camptothecin; DNA Damage; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan	1997
Intraperitoneal topoisomerase-I inhibitors. Preliminary findings with 9-aminocamptothecin. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Infusions, Parenteral; Neoplasms; Ovarian Neoplasms; Topoisomerase I Inhibitors	2000
The clinical development of 9-aminocamptothecin. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Humans; Neoplasms	2000
The development of camptothecin analogs in childhood cancers. The oncologist, 2001, Volume: 6, Issue:6 Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Humans; Infant; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan	2001

Trials

22 trial(s) available for 9-aminocamptothecin and Neoplasms

Article	Year
A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:4 Topics: Administration, Oral; Adult; Antineoplastic Agents; Area Under Curve; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Time Factors	2011
Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 days. Anti-cancer drugs, 2002, Volume: 13, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms	2002
Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:6 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms	2003
A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion. Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:4 Topics: Acetamides; Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Area Under Curve; Blood Cell Count; Camptothecin; Colloids; Drug Resistance, Neoplasm; Excipients; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms	2003
Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors. Cancer chemotherapy and pharmacology, 2004, Volume: 54, Issue:6 Topics: Administration, Oral; Camptothecin; Drug Administration Schedule; Humans; Neoplasms	2004
Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors. Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:5 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Camptothecin; Cross-Over Studies; Fasting; Female; Food; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms	2006
Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes. Investigational new drugs, 2006, Volume: 24, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP-Binding Cassette Transporters; Camptothecin; Female; Genotype; Humans; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Neoplasms; Polymorphism, Single Nucleotide	2006
Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen. Anti-cancer drugs, 2006, Volume: 17, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Time Factors	2006
Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Treatment Outcome	1996
Trials of 9-amino-20(S)-camptothecin in Boston. Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803 Topics: Adult; Antineoplastic Agents; Boston; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Female; Humans; Leukemia; Male; Middle Aged; Neoplasms	1996
Clinical pharmacology of 9-aminocamptothecin. Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803 Topics: Adult; Antineoplastic Agents; Camptothecin; Humans; Neoplasms; Topoisomerase I Inhibitors	1996
Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; Half-Life; Humans; Male; Middle Aged; Neoplasms	1997
Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Chromatography, High Pressure Liquid; Colloids; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Regression Analysis; Salvage Therapy	1998
Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion. Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Chemistry, Pharmaceutical; Colloids; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms	1998
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Cancer chemotherapy and pharmacology, 1998, Volume: 42, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Female; Humans; Male; Middle Aged; Neoplasms	1998
Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:7 Topics: Adolescent; Adult; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Male; Maximum Allowable Concentration; Neoplasms; Treatment Outcome; United States	1998
Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:8 Topics: Administration, Oral; Aged; Antineoplastic Agents; Biological Availability; Camptothecin; Capsules; Drug Administration Schedule; Humans; Injections, Intravenous; Intestinal Absorption; Middle Aged; Neoplasms	1998
A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:3 Topics: Adult; Aged; Anemia; Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Leukocytes, Mononuclear; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia	1995
Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva. Clinical pharmacology and therapeutics, 1999, Volume: 65, Issue:5 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Saliva	1999
Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Colloids; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Carriers; Female; Hematopoiesis; Humans; Infusions, Intravenous; Lactones; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Thrombocytopenia	1999
Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:7 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Least-Squares Analysis; Likelihood Functions; Male; Middle Aged; Neoplasms; Neutropenia; Pharmacokinetics; Thrombocytopenia	1999
A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients. Cancer chemotherapy and pharmacology, 2001, Volume: 48, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hematologic Tests; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Platelet Count	2001

Other Studies

3 other study(ies) available for 9-aminocamptothecin and Neoplasms

Article	Year
Identification of a small topoisomerase I-binding peptide that has synergistic antitumor activity with 9-aminocamptothecin. Molecular cancer therapeutics, 2006, Volume: 5, Issue:3 Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Camptothecin; DNA; DNA Topoisomerases, Type I; Drug Synergism; Humans; Mice; Mice, Nude; Molecular Sequence Data; Neoplasms; Oligonucleotides; Peptide Library; Peptides; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays	2006
Determination of the lactone and lactone plus carboxylate forms of 9-aminocamptothecin in human plasma by sensitive high-performance liquid chromatography with fluorescence detection. Journal of chromatography. B, Biomedical sciences and applications, 1997, Jul-04, Volume: 694, Issue:2 Topics: Antineoplastic Agents; Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Humans; Hydrogen-Ion Concentration; Lactones; Neoplasms; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence	1997
Why drugs fail: of mice and men revisited. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:2 Topics: Animals; Antineoplastic Agents; Biological Availability; Camptothecin; Enzyme Inhibitors; Humans; Mice; Neoplasms; Tissue Distribution; Topoisomerase I Inhibitors	2001